{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-175095","form_type":"8-K","ticker":"KLRS","cik":"0001754068","company_name":"Kalaris Therapeutics, Inc.","filed_at":"2023-06-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.387490+00:00","generated_at":"2026-06-13T17:11:16.937138+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"AlloVir prices public offering of 20M shares at $3.75/share for $75M gross","bullets":["Priced underwritten public offering of 20,000,000 shares at $3.75 per share; gross proceeds of $75.0M.","Net proceeds estimated at $70.2M ($80.7M if underwriters fully exercise 30-day option for 3M additional shares).","Offering expected to close on or about June 26, 2023; underwriters include J.P. Morgan, Morgan Stanley, and BofA.","Shares offered under existing shelf registration; 90-day lock-up for AlloVir executives and directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-175095","json":"https://secwatch.observer/filing/0001193125-23-175095.json","markdown":"https://secwatch.observer/filing/0001193125-23-175095.md","text":"https://secwatch.observer/filing/0001193125-23-175095.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1754068/000119312523175095/0001193125-23-175095-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1754068/000119312523175095/d472315d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T17:11:16.937138+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1b4d79e2d6b36299f5f41da70140a00d99a1fddd","claim":"Kalaris Therapeutics, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and BoFA Securities, Inc., as the representatives of the several underwriters valued at $3.75 per share (effective 2023-06-21).","evidence_excerpt":"On June 21, 2023, AlloVir, Inc. (“AlloVir”) entered into an underwriting agreement with J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and BoFA Securities, Inc., as the representatives of the several underwriters (the “Underwriters”) relating to an underwritten public offering of 20,000,000 shares of its common stock, par value $0.0001 per share, at a price to the public of $3.75 per share, less underwriting discounts and commissions.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312523175095/0001193125-23-175095-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and BoFA Securities, Inc., as the representatives of the several underwriters"},{"label":"Value","value":"$3.75 per share"},{"label":"Effective","value":"2023-06-21"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}